PSMA PET Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting psma pet clinical trials across 4 countries. Studies span Not Applicable, Phase 2, Phase 3. Top locations include Xianyang, Shaanxi, China, Yan’an, Shaanxi, China, Weinan, Shaanxi, China. Updated daily from ClinicalTrials.gov.


PSMA PET Trials at a Glance

7 actively recruiting trials for psma pet are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Xianyang, Yan’an, and Weinan. Lead sponsors running psma pet studies include Xijing Hospital, Convergent Therapeutics, and First Affiliated Hospital of Fujian Medical University.

Browse psma pet trials by phase

Treatments under study

About PSMA PET Clinical Trials

Looking for clinical trials for PSMA PET? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PSMA PET trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PSMA PET clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Not Applicable

PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy

PSMA PETProstate Cancer Screening
First Affiliated Hospital of Fujian Medical University230 enrolled1 locationNCT06923657
Recruiting

Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis

bone metastasisPSMA PETProstate Cancer (Diagnosis)+4 more
Xijing Hospital1,000 enrolled9 locationsNCT07553754
Recruiting

Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer

Treatment ResponseHigh-risk Prostate CancerPSMA PET+1 more
Xijing Hospital110 enrolled9 locationsNCT07553780
Recruiting
Not Applicable

68Ga-PSMA PET in the Renal Cell Carcinoma

MetastasesRenal CancerPSMA PET
Xijing Hospital300 enrolled9 locationsNCT04987086
Recruiting
Phase 3

PSMA PET Combined With MRI for the Detection of PCa

Prostate CancerProstatic NeoplasmPCA+6 more
Telix Pharmaceuticals (Innovations) Pty Limited204 enrolled1 locationNCT07052214
Recruiting
Phase 2

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics60 enrolled9 locationsNCT06549465
Recruiting

Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

Metastatic Prostate AdenocarcinomaPSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio University Hospital150 enrolled1 locationNCT06850545